Daiwa Securities Group’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.46M | Buy |
22,200
+21,849
| +6,225% | +$1.39M | ﹤0.01% | 712 |
|
|
2025
Q4 | $22K | Sell |
351
-25
| -7% | -$1.55K | ﹤0.01% | 1154 |
|
|
2025
Q3 | $21K | Sell |
376
-53
| -12% | -$2.18K | ﹤0.01% | 1137 |
|
|
2025
Q2 | $14K | Buy |
429
+40
| +10% | +$1.39K | ﹤0.01% | 1107 |
|
|
2025
Q1 | $16K | Hold |
389
| – | – | ﹤0.01% | 1078 |
|
|
2024
Q4 | $18K | Sell |
389
-45
| -10% | -$2.34K | ﹤0.01% | 1089 |
|
|
2024
Q3 | $23K | Hold |
434
| – | – | ﹤0.01% | 1094 |
|
|
2024
Q2 | $24K | Buy |
434
+53
| +14% | +$3.2K | ﹤0.01% | 1128 |
|
|
2024
Q1 | $27K | Hold |
381
| – | – | ﹤0.01% | 1125 |
|
|
2023
Q4 | $32K | Hold |
381
| – | – | ﹤0.01% | 1099 |
|
|
2023
Q3 | $11K | Hold |
381
| – | – | ﹤0.01% | 1121 |
|
|
2023
Q2 | $12K | Hold |
381
| – | – | ﹤0.01% | 1131 |
|
|
2023
Q1 | $13K | Hold |
381
| – | – | ﹤0.01% | 1093 |
|
|
2022
Q4 | $17K | Buy |
381
+62
| +19% | +$2.67K | ﹤0.01% | 1088 |
|
|
2022
Q3 | $15K | Hold |
319
| – | – | ﹤0.01% | 1108 |
|
|
2022
Q2 | $13K | Buy |
319
+74
| +30% | +$2.98K | ﹤0.01% | 1132 |
|
|
2022
Q1 | $9K | Hold |
245
| – | – | ﹤0.01% | 1143 |
|
|
2021
Q4 | $11K | Sell |
245
-41
| -14% | -$1.58K | ﹤0.01% | 1145 |
|
|
2021
Q3 | $10K | Buy |
286
+153
| +115% | +$4.5K | ﹤0.01% | 1139 |
|
|
2021
Q2 | $3K | Hold |
133
| – | – | ﹤0.01% | 1107 |
|
|
2021
Q1 | $3K | Hold |
133
| – | – | ﹤0.01% | 1103 |
|
|
2020
Q4 | $3K | Sell |
133
-230
| -63% | -$4.2K | ﹤0.01% | 1081 |
|
|
2020
Q3 | $8K | Hold |
363
| – | – | ﹤0.01% | 1055 |
|
|
2020
Q2 | $4K | Hold |
363
| – | – | ﹤0.01% | 1118 |
|
|
2020
Q1 | $4K | Hold |
363
| – | – | ﹤0.01% | 1113 |
|
|
2019
Q4 | $4K | Hold |
363
| – | – | ﹤0.01% | 1123 |
|
|
2019
Q3 | $4K | Hold |
363
| – | – | ﹤0.01% | 1086 |
|
|
2019
Q2 | $4K | Buy |
363
+65
| +22% | +$627 | ﹤0.01% | 1116 |
|
|
2019
Q1 | $2K | Hold |
298
| – | – | ﹤0.01% | 1129 |
|
|
2018
Q4 | $2K | Hold |
298
| – | – | ﹤0.01% | 1104 |
|
|
2018
Q3 | $3K | Hold |
298
| – | – | ﹤0.01% | 1104 |
|
|
2018
Q2 | $2K | Hold |
298
| – | – | ﹤0.01% | 1136 |
|
|
2018
Q1 | $2K | Buy |
+298
| New | +$2.56K | ﹤0.01% | 1124 |
|
Other funds holding CYTK
VPM
VCM
ACA
Daiwa Securities Group's CYTK Position: Q1 2026 in Review
Daiwa Securities Group increased its Cytokinetics (CYTK) stake by 6,225% in Q1 2026, buying an estimated $1.39M and bringing the position to 22,200 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #712.
Daiwa Securities Group first reported a position in CYTK in Q1 2018 and has held it in 33 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- Daiwa Securities Group held 22,200 shares of Cytokinetics worth $1.46M as of Q1 2026.
- Daiwa Securities Group bought 21,849 Cytokinetics shares in Q1 2026, an estimated $1.39M.
- Cytokinetics made up ﹤0.01% of Daiwa Securities Group's portfolio in Q1 2026, its #712 holding.
- Daiwa Securities Group first reported a position in Cytokinetics in Q1 2018 and has held it in 33 quarters since.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.